Quick Answer
AYTU BIOPHARMA, INC reported Cash and Equivalents of $30.95 million for fiscal year 2025.
AYTU BIOPHARMA, INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $30.95M | +54.7% |
| 2024 | $20.01M | -13.0% |
| 2023 | $22.98M | +18.7% |
| 2022 | $19.36M | -61.0% |
| 2021 | $49.65M | +3.3% |
| 2020 | $48.08M | +335.4% |
| 2019 | $11.04M | +57.5% |
| 2018 | $7.01M | +774.0% |
| 2017 | $802.3K | -90.0% |
| 2016 | $8.05M | +9.5% |
| 2015 | $7.35M | +178.6% |
| 2014 | $2.64M | -9.4% |
| 2013 | $2.91M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $30.02M | +47.2% | -8.0% |
| September 30, 2025 | $32.63M | +62.3% | +5.4% |
| June 30, 2025 | $30.95M | +54.7% | +70.3% |
| March 31, 2025 | $18.17M | -8.0% | -10.9% |
| December 31, 2024 | $20.40M | +4.4% | +1.4% |
| September 30, 2024 | $20.11M | +0.7% | +0.5% |
| June 30, 2024 | $20.01M | -13.0% | +1.2% |
| March 31, 2024 | $19.76M | +3.0% | +1.2% |
- AYTU BIOPHARMA, INC showed an increase of +54.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, AYTU BIOPHARMA, INC’s cash and equivalents has grown by 962.3% (from $2.91 million to $30.95 million).
- The most recent figure is from AYTU BIOPHARMA, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: